While the discipline of surgical pathology remains the traditional “gold standard” for clinical tissue diagnoses, technological advances in biomedical optics and quantitative image analysis are rapidly emerging as complimentary diagnostic tools for pathologists. As with all new medical technologies, investment justifications often need to be considered before formal reimbursement codes are established. Using the emerging technology of ex-vivo microscopy (EVM) as an example, this webinar will show how a business plan can be developed to justify investing in new technologies. This will be described from the perspective of a Section Chief or Department Chair proposing or agreeing to consider such a request; an Administrative Director providing the financial justification; and a Residency Program Director who must coordinate the engagement and training of pathologists and trainees in this new technology.
- Learn the components of a Business Plan and how to use them to financially justify an emerging technology
- Understand how to document the “value” of new technologies in terms of reduced costs, better quality and improved clinical outcomes.
- Discuss why pathologists need to be actively involved in the development and validation of emerging technologies.
- Understand how and why pathologists and trainees need to be engaged and educated about emerging technologies.
Wendy Wells, MD, MBBS, FCAP